Celcuity Inc. (NASDAQ:CELC) Given Average Rating of "Buy" by Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC - Get Free Report) have earned a consensus rating of "Buy" from the six research firms that are presently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $30.80.

Several equities research analysts have weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a research report on Monday, May 19th. Needham & Company LLC reissued a "buy" rating and issued a $29.00 price target on shares of Celcuity in a report on Thursday, May 15th.

Celcuity Price Performance

Shares of CELC traded down $0.45 during mid-day trading on Friday, reaching $12.11. The company had a trading volume of 115,413 shares, compared to its average volume of 290,578. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The company has a market capitalization of $458.56 million, a P/E ratio of -4.64 and a beta of 0.37. Celcuity has a twelve month low of $7.58 and a twelve month high of $19.77. The company's 50-day moving average is $10.68 and its 200-day moving average is $11.30.

Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.09. On average, equities analysts anticipate that Celcuity will post -2.62 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CELC. Rhumbline Advisers raised its stake in shares of Celcuity by 8.9% during the first quarter. Rhumbline Advisers now owns 42,194 shares of the company's stock worth $427,000 after buying an additional 3,439 shares during the last quarter. Baker BROS. Advisors LP boosted its stake in Celcuity by 59.0% in the first quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company's stock valued at $43,046,000 after acquiring an additional 1,579,182 shares during the last quarter. Paloma Partners Management Co acquired a new stake in Celcuity during the 1st quarter worth $215,000. Tema Etfs LLC bought a new stake in shares of Celcuity during the 1st quarter valued at $158,000. Finally, Trexquant Investment LP raised its position in shares of Celcuity by 131.3% during the 1st quarter. Trexquant Investment LP now owns 26,920 shares of the company's stock valued at $272,000 after acquiring an additional 15,280 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.